Case report: Senescence as mechanism of resistance to Pembrolizumab in a Lymphoma patient who failed CD19-Targeted CAR-T cell therapy.

MLA

De Matteis, Serena, et al. “Case Report: Senescence as Mechanism of Resistance to Pembrolizumab in a Lymphoma Patient Who Failed CD19-Targeted CAR-T Cell Therapy.” Frontiers in Immunology, vol. 13, Oct. 2022, p. 994731. EBSCOhost, https://doi.org/10.3389/fimmu.2022.994731.

APA

De Matteis, S., Casadei, B., Lolli, G., Dicataldo, M., Barbato, F., Dan, E., Paccagnella, A., Sinigaglia, B., Bertuzzi, C., Arcari, A., Zazzeroni, L., Bernuzzi, P., Laprovitera, N., Storci, G., Bertuccio, S. N., Ferracin, M., Bonafè, M., Zinzani, P. L., & Bonifazi, F. (2022). Case report: Senescence as mechanism of resistance to Pembrolizumab in a Lymphoma patient who failed CD19-Targeted CAR-T cell therapy. Frontiers in Immunology, 13, 994731. https://doi.org/10.3389/fimmu.2022.994731

Chicago

De Matteis, Serena, Beatrice Casadei, Ginevra Lolli, Michele Dicataldo, Francesco Barbato, Elisa Dan, Andrea Paccagnella, et al. 2022. “Case Report: Senescence as Mechanism of Resistance to Pembrolizumab in a Lymphoma Patient Who Failed CD19-Targeted CAR-T Cell Therapy.” Frontiers in Immunology 13 (October): 994731. doi:10.3389/fimmu.2022.994731.